In a study, the tumor burden, M2 macrophage polarization, and migration are reduced, and the response to immunotherapy with anti-PD-1 is enhanced by ladarixin, a CXCR1/2 dual-inhibitor [158]. Here, PDCD1 is linked to neoplasm.